BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen JA, Ma W, Yuan J, Li T. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors. Cancer Treat Res 2020;180:251-79. [PMID: 32215873 DOI: 10.1007/978-3-030-38862-1_9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhou JG, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, Ma H, Schubert P, Schweizer C, Fietkau R, Deutsch E, Gaipl U, Hecht M. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. J Immunother Cancer 2021;9:e001845. [PMID: 33593828 DOI: 10.1136/jitc-2020-001845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
2 Zhang T, Zheng S, Liu Y, Li X, Wu J, Sun Y, Liu G. DNA damage response and PD-1/PD-L1 pathway in ovarian cancer. DNA Repair (Amst) 2021;102:103112. [PMID: 33838550 DOI: 10.1016/j.dnarep.2021.103112] [Reference Citation Analysis]
3 Ma W, Pham B, Li T. Cancer neoantigens as potential targets for immunotherapy. Clin Exp Metastasis 2021. [PMID: 33950415 DOI: 10.1007/s10585-021-10091-1] [Reference Citation Analysis]
4 Bracci L, Fragale A, Gabriele L, Moschella F. Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy. Front Immunol 2020;11:582744. [PMID: 33193392 DOI: 10.3389/fimmu.2020.582744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ma W, Zeng J, Chen S, Lyu Y, Toomey KA, Phan CT, Yoneda KY, Li T. Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC. Biomark Res 2021;9:69. [PMID: 34488906 DOI: 10.1186/s40364-021-00324-6] [Reference Citation Analysis]